SARS-CoV-2 RapidPlex

From medical engineers at Caltech: “. . . we propose an ultrasensitive and low-cost telemedicine platform − the SARS-CoV-2 RapidPlex − based on target-specific immunoassays built off laser-engraved graphene for rapid and remote assessment of COVID-19 biomarkers (i.e., nucleocapsid protein, anti-spike protein IgG and IgM, and C-reactive protein). Multiplex sensing of these targets provides information on three key aspects of COVID-19 disease: viral infection, immune response, and disease severity. We successfully demonstrated the platform’s applicability using COVID-19 positive and negative serum and saliva samples. The SARS-CoV-2 RapidPlex has the potential to quickly and effectively triage patients and track infection progression, allowing for the clear identification of individuals who are infectious, vulnerable, and/or immune.     MORE

Image Credit; CalTech and Cell.com